Chest Medicine
Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.
14 Jan, 2022 | 08:37h | UTCFluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario
Related:
Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.
Commentary on Twitter
Thinking of prescribing fluvoxamine for covid 19? Ontario has a nice infographichttps://t.co/MKT8PqlJpM
— Todd C. Lee (@DrToddLee) January 12, 2022
Cohort Study: Patients who achieved weight loss through bariatric surgery may have lower risk for severe Covid-19 compared to patients who did not have surgical intervention for their obesity.
14 Jan, 2022 | 08:32h | UTCCommentaries:
Is COVID-19 the Newest Comorbidity of Obesity Mitigated by Bariatric Surgery? – JAMA Surgery
Can weight loss help protect against Covid-19? – CNN
Perspective: Omicron is forcing us to rethink mild COVID.
14 Jan, 2022 | 08:30h | UTCOmicron Is Forcing Us to Rethink Mild COVID – The Atlantic
RCT: Colchicine did not significantly reduce the need for intubation or 28-day mortality in patients hospitalized with Covid-19.
14 Jan, 2022 | 08:35h | UTCRelated:
M-A: Colchicine doesn’t lessen COVID-19 severity or stave off risk of death.
Commentary on Twitter
This randomized clinical trial found that colchicine did not significantly reduce mechanical ventilation or mortality in patients hospitalized with #COVID19 pneumonia. @DLBhattMD https://t.co/2nU5Ks74uF pic.twitter.com/VvHhTFnBhV
— JAMA Network Open (@JAMANetworkOpen) December 29, 2021
Observational study in adolescents showed the Pfizer-BioNTech vaccine had an overall effectiveness of 94% against hospitalization and 98% against critical Covid-19.
13 Jan, 2022 | 09:00h | UTCEditorial: Sparing of Severe Covid-19 in Vaccinated Adolescents – New England Journal of Medicine
Study shows COVID-19 vaccines offer lasting protection against hospitalization and death.
13 Jan, 2022 | 09:01h | UTCNews Release: Study shows COVID-19 vaccines offer lasting protection – University of North Carolina at Chapel Hill
An observational study in South Africa estimates the Pfizer vaccine had an effectiveness of 70% against hospitalization for Covid-19 caused by the omicron variant.
13 Jan, 2022 | 08:56h | UTCCommentary: BNT162b2 still effective, but less so, against Omicron – HealthDay
RCT: Early Remdesivir in outpatients can prevent progression to severe Covid-19.
13 Jan, 2022 | 08:54h | UTCEditorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right?
Commentary: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress
Commentary on Twitter
Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. #COVID19 #IDTwitter https://t.co/YFflw5nBxB pic.twitter.com/4NCD9AcnYH
— NEJM (@NEJM) December 22, 2021
Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized.
13 Jan, 2022 | 08:48h | UTCInvited Commentary: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
‘Killer’ immune cells still recognize Omicron variant.
13 Jan, 2022 | 08:51h | UTC‘Killer’ immune cells still recognize Omicron variant – Nature
See also: T-cells: the superheroes in the battle against omicron – The Conversation
A clinical case definition of post-COVID-19 condition by a Delphi consensus.
13 Jan, 2022 | 08:45h | UTC
Commentary on Twitter
New Review: A clinical case definition of post-#COVID19 condition by a Delphi consensus https://t.co/AoWBgCeMq5 pic.twitter.com/kAW1YY6kgr
— The Lancet Infectious Diseases (@TheLancetInfDis) December 22, 2021
The COVID-19 Treatment Guidelines Panel’s Statement on Anticoagulation in Hospitalized Patients With COVID-19 – in the absence of contraindications, use therapeutic-dose anticoagulation with low molecular weight heparin for hospitalized patients not in the ICU who have a D-dimer above the upper limit of normal.
12 Jan, 2022 | 09:11h | UTC
Statement on therapies for high-risk, nonhospitalized patients with mild to moderate Covid-19.
12 Jan, 2022 | 09:14h | UTCSee also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines
Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.
12 Jan, 2022 | 09:09h | UTCCommentaries:
Pfizer antiviral pills may be risky with other medications – NBC News
See also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines
Podcast: Long COVID Pearls.
12 Jan, 2022 | 09:04h | UTC#315 Long COVID with Dr. Monica Verduzco-Gutierrez – The Curbsiders
Perspective | Covid-19: Is it safe to reduce the self-isolation period?
12 Jan, 2022 | 09:00h | UTCCovid-19: Is it safe to reduce the self-isolation period? – The BMJ
German Guideline: Oxygen therapy in the acute care of adult patients.
12 Jan, 2022 | 08:57h | UTCGerman S3 Guideline: Oxygen Therapy in the Acute Care of Adult Patients – Respiration
Discriminative accuracy of chronic obstructive pulmonary disease screening instruments in 3 low- and middle-income country settings.
12 Jan, 2022 | 08:54h | UTCDiscriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Low- and Middle-Income Country Settings – JAMA (free for a limited period)
Editorial: Screening for Chronic Obstructive Pulmonary Disease: Unmet Needs and Future Considerations
News release: Simple screening for common lung disease could relieve millions globally – University College London
Commentary from the author on Twitter (thread – click for more)
🔺Screening for #COPD in LMIC🔺
The results of our @COPDGECo study from @ucl are published today in @JAMA_current.
Discriminative Accuracy of COPD Screening Instruments in Low- and Middle-Income Countries
🇳🇵🇵🇪 🇺🇬 https://t.co/7aq8XXfI8E – part of @JAMANetwork— John Hurst (@ProfHurst) January 11, 2022
RCT: Endoscopic sinus surgery with medical therapy vs. medical therapy alone for chronic rhinosinusitis with nasal polyps.
12 Jan, 2022 | 08:51h | UTCEndoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Commentary on Twitter
NEW Research—Endoscopic sinus surgery + medical therapy > medical therapy alone in pts w/ chronic rhinosinusitis w/ nasal polyps (although minimal clinically important difference was not met)
From Wytske Fokkens & colleagues https://t.co/VKxCQZ97Am pic.twitter.com/IzXq712lNL
— The Lancet Respiratory Medicine (@LancetRespirMed) January 8, 2022
RCT: Among patients younger than 21 years of age with provoked thromboembolism, anticoagulation for 6 weeks was non-inferior vs. 12 weeks on the risk of recurrence and bleeding events.
12 Jan, 2022 | 08:53h | UTCEffect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Duration of Anticoagulant Treatment for Acute Provoked Venous Thromboembolism in Pediatric Patients – JAMA (free for a limited period)
Cohort study: Among health care workers previously vaccinated with 2 doses of the Pfizer-BioNTech vaccine, receiving a third dose was associated with reduced risk of SARS-CoV-2 infection.
11 Jan, 2022 | 01:35h | UTCEditorial: Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection – JAMA
Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.
11 Jan, 2022 | 01:33h | UTC
Commentary on Twitter
In @NEJM today, @TerezaKasaeva @doctorsoumya and I write about
Covid-19’s devastating impact on tuberculosis care & offer suggestions for recoveryhttps://t.co/buOEOPVWwM pic.twitter.com/BfOK3X3MuU
— Madhu Pai, MD, PhD (@paimadhu) January 5, 2022
Review: Rapid diagnostic testing for SARS-CoV-2.
11 Jan, 2022 | 01:34h | UTCRapid Diagnostic Testing for SARS-CoV-2 – New England Journal of Medicine
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19.
11 Jan, 2022 | 01:26h | UTC
Commentary on Twitter
Fantastic outpatient treatment approach from Ontario #COVID19 Clinical Practice Guidelines
Risk level:high mod low
Eg:high:Sotrovimab is recommended if NA Remdesivir if NA Fluvoxamine or Budesonide
Paxlovid/Molnupiravir not added coz not yet approved CA https://t.co/dDhj6vA0uv pic.twitter.com/4ucrKIcMn8— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) January 8, 2022
M-A: Fatigue and cognitive impairment in Post-COVID-19 Syndrome.
11 Jan, 2022 | 01:28h | UTC